Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

Published on :

MALVERN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data Safety and Monitoring Board (DSMB) for the OCU400 clinical trial recently convened and established high dose as the maximum tolerable dose (MTD) in the dose-escalation phase of the study.
“The DSMB has recommended moving forward to dose subsequent subjects with NR2E3 and RHO gene mutations associated with Retinitis Pigmentosa (RP) and CEP290 gene mutations associated with Leber Congenital Amaurosis (LCA) at the targeted dose in the expansion phase of the study,” said Dr. Peter Y. Chang, MD, FACS, Massachusetts Eye Research & Surgery Institution, DSMB Chair for the OCU400 clinical trial. “No serious adverse events (SAEs) related to OCU400 have been reported to date.”

5 Philadelphia Area Bioscience Companies Fighting Infectious Diseases

Published on :

Philadelphia is a blossoming biotech cluster across a wide array of fields and market sectors. Cell and gene therapy is a rapidly growing sector; the area has a deep and diversified life sciences talent pool; medtech companies are thriving and are poised for even more growth; and a bevy of Philadelphia bioscience organizations have a focus on battling COVID-19 and preparing for the next infectious disease to threaten public health.

Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’

Published on :

Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Business Journal named the Company among the “2022 Best Places to Work.”